abstract |
The present disclosure is to provide the use of A 3 R agonists such as IB-MECA to reduce intraocular pressure (IOP) in subjects, particularly human subjects. Similarly, the present invention provides pharmaceutical compositions and methods for reducing IOP in a subject using an A 3 R agonist. |